open access publication

Article, 2024

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Cardiovascular Diabetology, ISSN 1475-2840, Volume 23, 1, Page 104, 10.1186/s12933-024-02180-8

Contributors

Schnell, Oliver (Corresponding author) [1] Barnard-Kelly, Katharine D 0000-0002-3888-3123 [2] Battelino, Tadej 0000-0002-0273-4732 [3] [4] Ceriello, Antonio 0000-0001-8122-3203 [5] Larsson, Helena Elding 0000-0003-3306-1742 [6] [7] Fernandez-Fernandez, Beatriz 0000-0002-6727-1943 [8] Forst, Thomas [9] Frias, Juan-Pablo [10] Gavin, James R. [11] Giorgino, Francesco 0000-0001-7372-2678 [12] Groop, Per-Henrik 0000-0003-4055-6954 [13] [14] Heerspink, Hiddo J. L. [15] [16] Herzig, Stephan [17] Hummel, Michael [1] Huntley, George [18] Ibrahim, Mahmoud [19] Itzhak, Baruch [20] [21] Jacob, Stephan [22] Ji, Linong [23] Kosiborod, Mikhail Naum [24] Lalic, Nebosja [25] [26] Macieira, Sofia [27] Malik, Rayaz Ahmed 0000-0002-7188-8903 [28] Mankovsky, Boris [29] Marx, Nikolaus [30] Mathieu, C Chantal 0000-0002-4055-5233 [31] Müller, Timo Dirk 0000-0002-0624-9339 [32] [33] Ray, Kausik [34] Rodbard, Helena W. [35] Rossing, Peter R 0000-0002-1531-4294 [36] [37] Rydén, Lars E 0000-0002-5430-4697 [38] Schumm-Draeger, Petra-Maria [39] Schwarz, Peter [40] Škrha, Jan [41] Snoek, Frank Jan 0000-0001-9563-6762 [42] Tacke, Frank 0000-0001-6206-0226 [43] Taylor, Bruce [44] Jeppesen, Britta Tendal [45] Tesfaye, Solomon Hailemariam 0009-0005-7486-464X [46] [47] Topsever, Pinar 0000-0001-7119-8569 [48] Vilsbøll, Tina 0000-0002-0456-6787 [36] [37] Yu, Xuefeng 0000-0003-3961-9321 [49] [50] Standl, Eberhard [1]

Affiliations

  1. [1] Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany
    2. [NORA names: Germany; Europe, EU; OECD];
  2. [2] Southern Health NHS Foundation Trust
    3. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  3. [3] Ljubljana University Medical Centre
    4. [NORA names: Slovenia; Europe, EU; OECD];
  4. [4] University of Ljubljana
    5. [NORA names: Slovenia; Europe, EU; OECD];
  5. [5] MultiMedica
    6. [NORA names: Italy; Europe, EU; OECD];

Abstract

The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).

Keywords

Cardiovascular, Congress, GLP-1, HFpEF, MACE, SGLT2, SGLT2 inhibitors, T1D, acid, advances, adverse cardiovascular events, agonists, antagonist, approach, assess treatment efficacy, association, association of diabetes, audience, bempedoic acid, cancer, cardiologists, cardiovascular disease, cardiovascular events, cardiovascular outcome trials, care physicians, chronic diseases, chronic kidney disease, clearing, clearing outcome, clinical trials, communication strategies, comorbidities, complications, continuous glucose monitoring, dapagliflozin, dementia, diabetes, diabetologists, discussion, disease, effect, efficacy, endocrinologists, ethnic groups, events, exchange, failure, glucose monitoring, group, guidelines, heart, heart failure, implementation, improve metabolic outcomes, inhibitors, innovative approach, keys, kidney, kidney disease, management, management of cardiovascular disease, management of chronic kidney disease, management of diabetes, management of type 1 diabetes, medication, metabolic outcomes, metabolism, mineralocorticoid receptor antagonists, minimal side effects, monitoring, nephrologists, non-steroidal mineralocorticoid receptor antagonist, nonalcoholic steatohepatitis, obesity, obesity-related heart failure, online discussions, outcome trials, outcomes, patient-reported outcomes, patients, physicians, platform, primary care physicians, receptor agonists, receptor antagonist, risk, semaglutide, side effects, steatohepatitis, strategies, summit, technology, treatment, treatment efficacy, treatment of chronic diseases, treatment of obesity, trials, type 1 diabetes

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+